Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an announcement.
Ascletis Pharma has begun dosing the first participants in a 13-week, randomized Phase II trial in the U.S. to evaluate its oral small molecule GLP-1 receptor agonist ASC30 for the treatment of type 2 diabetes, with topline data expected in the third quarter of 2026. The move follows a recently completed 13-week U.S. Phase II obesity study, in which once-daily ASC30 tablets achieved up to 7.7% placebo-adjusted weight loss with favorable gastrointestinal tolerability and a low discontinuation rate, reinforcing the drug’s potential best-in-class profile and supporting Ascletis’s strategic push into the sizeable diabetes market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, including obesity and type 2 diabetes. The company’s pipeline includes ASC30, an in-house discovered small molecule GLP-1 receptor agonist designed for oral and injectable dosing to address large and growing markets in diabetes and obesity treatment.
Average Trading Volume: 5,435,962
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.16B
See more data about 1672 stock on TipRanks’ Stock Analysis page.